In order to participate in this study, a subject must meet all of the eligibility criteria outlined below.
Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. Subjects are willing and able
to comply with study procedures based on the judgment of the investigator.
Age ≥ 18 years at the time of consent.
ECOG or Karnofsky Performance Status of 0 or 1
You may not be if
Active infection requiring systemic therapy.
Pregnant or breastfeeding.
Prior ipsilateral invasive breast, chest wall or thoracic radiotherapy
Prior ipsilateral invasive breast cancer, contralateral breast cancer or a known
additional, invasive malignancy that is progressing or required active treatment in
the last 5 years
Clareo Health | Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
